Findings

What do systematic reviews say?

214 questions · 217 findings · 40 reviews · Pain, Palliative and Supportive Care

Sort:Best matchNewest Highest certainty Download CSV

No studies found 35 · 16.1%GRADE not reported 2 · 0.9%Very low 49 · 22.6%Low 43 · 19.8%Moderate 48 · 22.1%High 40 · 18.4%

Intervention not reported

Headache relief at 2 h · adults with migraine headache ‐ moderate or severe pain

1 finding from 1 review

Diclofenac with or without an antiemetic for acute migraine headaches in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1447 participants
Moderate

Intervention not reported

Sustained pain‐free at 24 h · adults with migraine headache ‐ moderate or severe pain

1 finding from 1 review

Diclofenac with or without an antiemetic for acute migraine headaches in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1578 participants
Moderate

Intervention not reported

Sustained headache relief at 24 h · adults with migraine headache ‐ moderate or severe pain

The review found no eligible studies for this question.

1 finding from 1 review

Diclofenac with or without an antiemetic for acute migraine headaches in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

At least one AE · adults with migraine headache ‐ moderate or severe pain

1 finding from 1 review

Diclofenac with or without an antiemetic for acute migraine headaches in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1075 participants
Low

Intervention not reported

Serious AE · adults with migraine headache ‐ moderate or severe pain

The review found no eligible studies for this question.

1 finding from 1 review

Diclofenac with or without an antiemetic for acute migraine headaches in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Naproxen 500 mg or 825 mg vs placebo

Pain‐free at 2 hours · migraine headache ‐ moderate or severe pain

1 finding from 1 review

Naproxen with or without an antiemetic for acute migraine headaches in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Naproxen 500 mg or 825 mg vs placebo

Headache relief at 2 h · migraine headache ‐ moderate or severe pain

1 finding from 1 review

Naproxen with or without an antiemetic for acute migraine headaches in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Naproxen 500 mg or 825 mg vs placebo

Sustained pain‐free at 24 h · migraine headache ‐ moderate or severe pain

1 finding from 1 review

Naproxen with or without an antiemetic for acute migraine headaches in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Naproxen 500 mg or 825 mg vs placebo

Sustained headache relief at 24 h · migraine headache ‐ moderate or severe pain

1 finding from 1 review

Naproxen with or without an antiemetic for acute migraine headaches in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Moderate

Naproxen 500 mg or 825 mg vs placebo

Number of participants reporting an adverse event · migraine headache ‐ moderate or severe pain

1 finding from 1 review

Naproxen with or without an antiemetic for acute migraine headaches in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Naproxen 500 mg or 825 mg vs placebo

Serious AE · migraine headache ‐ moderate or severe pain

The review found no eligible studies for this question.

1 finding from 1 review

Naproxen with or without an antiemetic for acute migraine headaches in adults 2013 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

casopitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

rolapitant + granisetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Moderate

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

rolapitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
39 studies · 21642 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

aprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Very low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

fosaprepitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

casopitant + ondansetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

netupitant + palonosetron · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
23 studies · 16065 participants
Low